General MedicationsPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDERStandard
LAMZEDE
VELMANASE ALFA-TYCV
Standard Dose
10MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary
Approval overview LAMZEDE is listed in Drugs@FDA under application 761278 (BLA).
Review priority: PRIORITY Marketing status: Prescription Active ingredient VELMANASE ALFA-TYCV Form and strength POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER - 10MG Sponsor CHIESI FARMACEUTICI SPA Submission history Latest submission status date: 2023-02-16 00:00:00.
Structured Monograph
Clinical summary
Approval overview LAMZEDE is listed in Drugs@FDA under application 761278 (BLA). Review priority: PRIORITY Marketing status: Prescription Active ingredient VELMANASE ALFA-TYCV Form and strength POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER - 10MG Sponsor CHIESI FARMACEUTICI SPA Submission history Latest submission status date: 2023-02-16 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.